Ralph Henderson, MD
Urology · Shreveport, LANPI 1164427621
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (54.3%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 39 manufacturers reported payments, led by Johnson & Johnson at 47.0% of the total. Reporting peaked in 2019 at $58,071 and has fallen 66.6% since, to $19,422 in 2025. Among urology clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 477 payments — averaging $442.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$99K
- SN Holdings, LLC$24K
- Bayer$14K
- Janssen Scientific Affairs, LLC$10K
- Pfizer$10K
- Clovis Oncology, Inc.$7K
- plus $48K from 33 others
Across 517 payments — averaging $7303.62 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$1.7M
- Pfizer$1.1M
- Siemens Medical Solutions USA, Inc.$319K
- Dendreon Pharmaceuticals LLC$167K
- Urogen Pharma, Inc.$154K
- Telix Pharmaceuticals$99K
- plus $290K from 12 others
What the payments were for
- Consulting fees$57,45227%
- Speaking & faculty fees$114,59854%
- Travel & lodging$23,51911%
- Food & beverage$15,2287%
- Education$770%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 139 | $99,013 |
| SN Holdings, LLC | 33 | $23,629 |
| Bayer | 25 | $14,094 |
| Janssen Scientific Affairs, LLC | 8 | $9,705 |
| Pfizer | 35 | $9,676 |
| Clovis Oncology, Inc. | 11 | $6,897 |
| Astellas Pharma US Inc | 25 | $6,502 |
| Urogen Pharma, Inc. | 7 | $6,307 |
| Tolmar Pharmaceuticals, Inc. | 8 | $4,104 |
| AstraZeneca | 7 | $4,063 |
| Ferring Pharmaceuticals Inc. | 5 | $3,827 |
| Foundation Medicine, Inc. | 2 | $3,256 |
| Photocure Inc | 1 | $3,000 |
| Immunitybio, Inc. | 4 | $2,606 |
| Progenics Pharmaceuticals, Inc. | 2 | $2,568 |
| Janssen Global Services, LLC | 2 | $2,520 |
| Dendreon Pharmaceuticals LLC | 12 | $2,501 |
| Verity Pharmaceuticals Inc. | 11 | $1,189 |
| Urogpo LLC | 4 | $1,146 |
| Sumitomo Pharma America, Inc. | 39 | $1,030 |
| Novartis | 24 | $582 |
| Teleflex LLC | 4 | $543 |
| Myriad Genetic Laboratories, Inc. | 9 | $388 |
| Boston Scientific | 3 | $329 |
| Myovant Sciences Inc. | 8 | $231 |
| Merck | 7 | $182 |
| AbbVie(2 entities) | 9 | $162 |
| Axonics, Inc. | 4 | $141 |
| Coloplast | 6 | $130 |
| Endo Pharmaceuticals Inc. | 6 | $116 |
| Blue Earth Diagnostics | 4 | $101 |
| Intuitive Surgical | 1 | $88 |
| Olympus America Inc. | 3 | $69 |
| Tolmar, Inc. | 2 | $42 |
| Sanofi | 2 | $41 |
| Antares Pharma, Inc. | 2 | $38 |
| Procept Biorobotics Corporation | 1 | $24 |
| Medtronic | 1 | $20 |
| Neotract Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Erleada$91,502
- AKEEGA$14,792
- XTANDI$11,133
- Nubeqa$9,181
- Rubraca$6,629
- RYBREVANT$6,460
- CARVYKTI$6,460
- Xofigo$4,159
- ELIGARD$3,900
- ADSTILADRIN$3,756
- FOUNDATIONACT$3,256
- FOUNDATIONFOCUS$3,256
- FOUNDATIONONE CDX$3,256
- FOUNDATIONONE HEME$3,256
- FOUNDATIONONE$3,256
- Cysview$3,000
- PYLARIFY$2,568
- LYNPARZA$2,558
- ANKTIVA$2,500
- ZUSDURI$2,368
How this compares
$210,873 in reported general payments places this provider in the 95th percentile of 199 urology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OrgovyxRelugolix | 37 | $102,249 |
| GemtesaVibegron | 88 | $55,621 |
| Tamsulosin Hcl | 743 | $8,855 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 104 | $3,412 |
| Finasteride | 231 | $1,892 |
| Methenamine Hippurate | 21 | $1,718 |
| Estradiol | 24 | $1,500 |
| Oxybutynin Chloride ErOxybutynin Chloride | 57 | $1,495 |
| Testosterone | 12 | $1,001 |
| Trimethoprim | 28 | $938 |
| Solifenacin Succinate | 24 | $870 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 43 | $664 |
| Dutasteride | 25 | $656 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 47 | $624 |
| Trospium Chloride | 13 | $550 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Orgovyx, Gemtesa | $1,030 | $157,870125 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 199 urology providers in Louisiana.
Other urology in Shreveport
- Kevin HebertShreveport$54K
- Nazih KhaterShreveport$23K
- David PriceShreveport$23K
- Jared MossShreveport$17K
- Tajammul FaziliShreveport$16K
- Ashley BakerShreveport$13K
- Kevin ClineShreveport$12K
- Adam StageShreveport$8K
- Jeremy NorwoodShreveport$8K
- Richard VanlangendonckNew Orleans$289K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.